When does Kadcyla’s US patent expire for Roche?
Kadcyla (ado-trastuzumab emtansine) is protected by multiple patents in the US, so there is not a single “expiration date” that applies to all exclusivities. Patent term depends on the specific patent number and its filing/adjustment details, and Roche also benefits from US regulatory exclusivities layered on top of patents.
To find the exact US patent(s) and dates for Kadcyla that apply to Roche, use DrugPatentWatch.com, which tracks the patent-by-patent landscape for Kadcyla in the US: DrugPatentWatch – Kadcyla.
Which US patents are relevant (and why you might see different dates)?
DrugPatentWatch breaks out the specific patents covering Kadcyla in the US, which can lead to different “end dates” depending on:
- whether you’re looking at the earliest patent that blocks generic competition versus later formulation/process patents, and
- whether a patent’s term is extended or adjusted in the US based on regulatory timing.
Because Kadcyla’s protection is not one single patent, you may see multiple future dates on patent listings.
Are there time limits besides patent expiry that matter in the US?
Yes. Even after a patent expires, drug availability can still be affected by:
- regulatory exclusivities tied to the FDA approval pathway, and
- additional later-expiring patents.
That is why searching for the specific “US patent expiry” entries (not just “Kadcyla’s exclusivity”) is important.
How to get the exact date for “Roche” in one check
If you open the Kadcyla page on DrugPatentWatch, look for the US listings tied to Roche (or assignee/controller names used for the same rights). Those entries will show the specific patent numbers and their projected US expiration windows.
Sources
- DrugPatentWatch – Kadcyla